Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMU 201

Next Previous
X
Search
Drug Profile

IMU 201

Alternative Names: APi-2568; IMU-201; KEY-Vaxx; PD-1 (KEY-Vaxx); PD-1 cancer vaccine - Imugene; PD-1 vaccine; PD1-Vaxx; PDI Vaxx

Latest Information Update: 05 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mayo Clinic; Ohio State University
  • Developer Imugene
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cancer
  • Phase I Non-small cell lung cancer
  • Preclinical Colorectal cancer

Most Recent Events

  • 01 Dec 2024 Imugene plans a phase III trial for Colorectal Cancer in UK in December 2024 (IM) (NCT06692959)
  • 08 Sep 2024 Preclinical development is ongoing in Australia for Colorectal cancer
  • 07 Aug 2024 IMU 201 is still in phase I IMPRINTER trial for Non-small cell lung cancer (Combination therapy, Monotherapy, Late-stage disease) in Australia and USA (IM) (NCT04432207)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top